Taiwanese air force jet makes ‘hard landing’ in Hawaii

In the second incident in a week, a Taiwanese air force F-16 fighter jet had to make an emergency landing in Hawaii on Monday due to landing gear problems, media reports said.

Hawaii News Now said the fighter made a “hard landing” at Honolulu airport, coming to rest on its nose because “the landing gear on the aircraft didn’t deploy.”

No one was injured in the incident, which happened on Monday afternoon, the news portal said. A runway was closed for hours while crews worked to move the aircraft. 

Taiwan’s Ministry of National Defense has yet to provide any comment on the incident, the second related to U.S.-made F-16 aircraft this year.

In mid-January an F-16V, one of the most advanced fighters in Taiwan’s possession, crashed in the sea off the west coast of the island, killing its sole pilot.

The Taiwanese air force suspended F-16 combat training for over a week but resumed in late January.

On May 31, an air force pilot died when his AT-3 Tzu Chung jet trainer crashed in southern Taiwan.

F-16V 2.jpg
Taiwan Air Force’s refitted F-16V jets taking off. CREDIT: CNA

Upgrading the fleet

The aircraft at Honolulu airport, believed to be a F-16A/B version, was en route from Luke Air Force Base in Arizona to Taiwan, the national Central News Agency (CNA) reported.

Currently 10 F-16 fighters are stationed at the Arizona base for training. They are part of Taiwan’s program to upgrade 140 F-16A/B aircraft to F-16V status at a total cost of NT$110 billion or U.S. $3.72 billion.

Taiwan has ordered 66 new F-16V fighter jets from the U.S. defense giant Lockheed Martin for an undisclosed amount. The jets are expected to be delivered by late 2026 and will be stationed at Zhihang Air Force Base in Taitung County.

In 2019, the U.S. approved the sale of U.S. $8 billion in arms to Taiwan, including the F-16Vs.

Willem Appelo to succeed Sophie Bechu as Philips’ Chief Operations Officer

June 7, 2022

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that Willem (Wim) Appelo will join Philips’ Executive Committee, effective July 18, 2022, and succeed Sophie Bechu as Chief Operations Officer per October 1, 2022. Mr. Appelo will report to Philips CEO Frans van Houten and work closely with Mrs. Bechu to ensure a seamless transition. Mrs. Bechu, who joined Philips in 2016, will step down from her role on October 1, 2022, after which she will work on project-based initiatives until she retires at the end of January, 2023.

Mr. Appelo (Dutch, 1964) will join Philips after having worked as interim Supply Chain Officer, and with private equity firms in the medical technology industry for the last year. Before that, he was Vice President Supply Chain Strategy, Innovation & Deployment at Johnson & Johnson, where he led the Enterprise Supply Chain Global Strategy and Innovation team across the company’s three operating segments: Pharma, Consumer Health, and Medical Devices. Prior to that, Mr. Appelo was Johnson & Johnson’s Vice President Supply Chain Medical Devices. Prior to joining Johnson & Johnson, he held various senior positions at Xerox Corporation, ultimately as President, Global Delivery and Technology Group, where he was responsible for Xerox’s then newly-created Global Supplies Business Group.

“I am very pleased that Wim Appelo will be joining Philips as our new Chief Operations Officer,” said Frans van Houten, CEO of Royal Philips. “Wim brings a wealth of relevant experience to Philips, adding in-depth knowledge and understanding of medical technology and informatics supply chain management, which will help Philips accelerate its journey to becoming a health technology solutions leader. I want to thank Sophie for her highly valuable contribution to Philips and her relentless focus and deep commitment to establishing Philips’ Integrated Supply Chain organization since joining in 2016. During that time, she successfully optimized our supplier base and manufacturing footprint, continually driving operational excellence with a customer-first mindset.”

Mr. Appelo’s appointment to Philips’ Executive Committee builds on last year’s appointment of Shez Partovi, MD, as Chief Medical, Innovation & Strategy Officer, and member of Philips’ Executive Committee. Dr. Partovi brings highly relevant experience to Philips given his prior roles as neuroradiologist at the Barrow Neurological Institute, Chief Digital Officer at Dignity Health, and Worldwide Head of Healthcare, Life Sciences and Medical Devices at Amazon Web Services (AWS). Philips has continued to strengthen its senior management across the company with the appointment of 30 experienced healthcare and medical technology leaders over the past three years.

Additional information on Philips’ Executive Committee can be found here.

For further information, please contact:

Ben Zwirs
Philips Global Press Office
Tel.: +31 6 1521 3446
E-mail: ben.zwirs@philips.com

Derya Guzel
Philips Investor Relations
Tel.: +31 20 59 77055
E-mail: derya.guzel@philips.com

About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2021 sales of EUR 17.2 billion and employs approximately 79,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Attachment

crop.zone Secures USD 11 Million Equity Funding

Keeping an eye on the world market: crop.zone strengthens its capital base for serial production

Dirk Vandenhirtz CEO – Founder

Dirk Vandenhirtz CEO – Founder

AACHEN, Germany, June 07, 2022 (GLOBE NEWSWIRE) — Good news for herbicide-free agriculture. crop.zone, manufacturer of the volt.fuel Electrical Weeding System, has significantly strengthened its capital base for entering into serial production.

Existing shareholders (incl. Nufarm Limited) and new financial investors (Demeter Investment Managers, Madaus Capital Partners) have increased the equity base of the Aachen-based company by almost 11 million USD.

The innovative crop.zone system offers a natural organic alternative to non-selective synthetic herbicides such as Glyphosate or Diquat. As a highly productive and efficient solution, it is also used in desiccation applications and seedbed preparation.  crop.zone’s system is currently being successfully applied in Europe. It is available through crop.zone’s partners Nufarm, Kamps de Will and fenaco.

crop.zone’s and investors’ objectives for the USD 11 million investment are to open up new international markets and to develop additional agronomic treatment patterns for the crop.zone system.

“Our focus is investing in people, production and scaling. crop.zone will change agriculture by giving the industry a tool to work in a more sustainable and organic manner. Our ambition is to rethink the way we farm,” says CEO Dirk Vandenhirtz, highlighting the key issue that agriculture faces today and that crop.zone aims to address with its renewed investment.

Intellectual property is the key when starting serial production of the system, which is already in use in Germany, the Netherlands and Switzerland.

“We see the new investment as a great vote of confidence from our partners which shows a high level of trust in the path to a product ready for serial production. crop.zone is now a mature technology that solves problems in international agriculture. It is easy for farmers to use, renders the use of harmful herbicides superfluous and enables  a major contribution to CO2-reduced agriculture,” Dirk Vandenhirtz continues.

crop.zone’s existing shareholders, who have co-invest in the current financing round, include Nufarm Limited, a leading developer and manufacturer of crop protection solutions and seed technologies. The company, which has more than 2,500 employees, serves major agricultural markets in Europe, North America and Asia Pacific and is headquartered in Melbourne, Australia. Nufarm Regional General Manager EuMEA, Hildo Brilleman, says that Nufarm was proud to strengthen its existing partnership with crop.zone as it continues to build on its expanding portfolio of sustainable solutions for farmers:

“This new funding round allows crop.zone to expand their technology into new crops and segments. We are proud to be part of this journey to develop a sustainable potato desiccation and weed control offer for European farmers. Full commercialization of NUCROP will begin this year after a successful trial season in various European countries. As a key partner for commercialization, Nufarm will market the crop.zone solution under its own brand NUCROP across our distribution partners for Ag inputs and farm equipment.”

The investment by Demeter Investment Managers, a major European player in venture capital and private equity for the ecological transition, shows the importance of crop.zone system’s unique selling point – an alternative to pesticides in farming. Demeter Managing Partner Cyrille Cabaret says:

“At Demeter Investment Managers, we believe there is an urgent need to find alternatives to chemical non-selective herbicides in agriculture. The electrical hybrid technology developed by crop.zone offers farmers an effective, competitive, and organic solution for crop management. We are thrilled to accompany the crop.zone team in this new development phase alongside renowned partners like Nufarm, LBBZ and Madaus Capital Partners.”

Through its subsidiary RWTH Innovation, RWTH continues to support crop.zone in the current financing round. crop.zone had already been supported to get going by participating in the RWTH Innovation Sprint, a pre-seed funding mechanism by RWTH Innovation supported by the Exzellenz Start-up Center.NRW initiative of the NRW Ministry for Economic Affairs. The Innovation Sprint helped crop.zone to build a prototype and thus validate the business case of their technology.

“Then, as now, the potential of an environmentally impactful technology embedded in the regional research and innovation ecosystem and run by a team with a profound industry expertise has been the key argument for us to get involved”, says Bram Wijlands, Managing Director at RWTH Innovation. “This technology fully embodies the spirit of RWTH Aachen being the seedbed for profound tech innovations.”

Further information please contact us at
info@crop.zone crop.zone PR

  • Germany:  +49 2408 59 80 333
  • Netherlands:  +31 850659277
  • France:   +33 0970 445 443
  • United States: +1 (919) 251 -6320
  • Switzerland: +41 (44) 585 34 88
  • Hong Kong SAR: +852 8193 0287
  • United Kingdom: +44 020 8133 7059

Related Images

Image 1: Dirk Vandenhirtz CEO – Founder

Dirk Vandenhirtz CEO and founder of crop.zone

This content was issued through the press release distribution service at Newswire.com.

Attachment

MRM Health Reports Preclinical Results Showing a 9-Strain Bacterial Consortium Delays Non-Alcoholic Fatty Liver Disease Progression and Liver Fibrosis

GHENT, Belgium, June 07, 2022 (GLOBE NEWSWIRE) — MRM Health, a clinical-stage biopharmaceutical company developing next-generation live microbiome consortia therapeutics, announces the publication of preclinical research relating to its ongoing program in non-alcoholic fatty liver disease (NAFLD), with a 9-strain live bacterial consortium resulting from its proprietary and unique CORAL® platform technology.

The research was conducted in collaboration with the lab of leading experts Dr. Salvador Augustin (MD) and Dr. Maria Martell of the Liver Unit within the Department of Internal Medicine at the University Hospital of Vall d’Hebron (Barcelona, Spain). The work demonstrates that a live bacterial consortium of 9 rationally selected gut commensal strains was able to improve portal hypertension, insulin signaling and NAFLD activity score at histopathology and to prevent fibrosis development in two different in vivo disease models of Non-Alcoholic Steatohepatitis (NASH). The bacterial consortium also improved endothelial function and re-balanced the gut microbiome in the disease models.

NAFLD, and its progressive form NASH, is the hepatic manifestation of the metabolic syndrome and has a rapidly increasing prevalence, with about 20-30% of the general adult population suffering from NAFLD. Progression of NAFLD into NASH and cirrhosis becomes irreversible, yet no registered treatment is available to date. Leveraging on its breakthrough CORAL® platform, MRM Health identified and developed the 9-strain bacterial consortium, based on a combination of mechanisms-of-action linked to NAFLD.

“These preclinical results are highly important as there are to date no approved therapies for NASH or portal hypertension and the field urgently needs new approaches,” commented Dr. Maria Martell “Microbiome-based manipulation of the gut-liver axis can offer a completely novel treatment strategy for NASH and holds much promise for the full spectrum of liver disease”.

“We believe live bacterial consortia have transformational potential for metabolic and liver diseases,” said Nigel Horscroft, D.Phil., Chief Scientific Officer of MRM Health. “These recent advancements from MRM Health scientists and our academic partner highlight the potential of Live Biotherapeutic Products developed through our CORAL® platform to impact serious diseases, including NASH and Ulcerative Colitis (UC), upon which existing therapeutic modalities have had little impact.”

The results will also be presented as a poster at the International Liver Congress 2022 in London (UK), June 22-26, 2022.

Publication: Pinheiro et al. 2022, Biomedicines, A Nine-Strain Bacterial Consortium Improves Portal Hypertension and Insulin Signaling and Delays NAFLD Progression In Vivo (https://www.mdpi.com/2227-9059/10/5/1191#)

About MRM Health

MRM Health NV, Ghent, Belgium, is a biopharmaceutical company focused on the development of next-generation optimized consortium therapeutics based on the human microbiome. The company has built a diversified pipeline with its proprietary CORAL® platform to design, optimize, and manufacture bacterial consortia as single drug substance. Its most advanced program MH002 is an optimized consortium of 6 rationally-selected and well-characterized commensal strains. MH002 is currently being studied in a Phase 1b/2a study in patients with mild-to-moderate ulcerative colitis and a second clinical study is in start-up. Additional pipeline development includes a preclinical program in Parkinson’s disease, preclinical programs in Type 2 Diabetes and in NAFLD (both partnered with IFF Nutrition Biosciences, previously DuPont), and a discovery program in autoimmune disease, including spondyloarthritis.

About CORAL®

MRM Health’s differentiating CORAL® platform utilizes a bioinformatics-guided in-human discovery engine combined with a breakthrough in optimization and manufacturing of consortia as single drug substance. The proprietary consortia optimization technology allows to develop next-generation consortia therapeutics with faster onset-of-action and increased potency and robustness. The breakthrough scalable, robust, and standardized cGMP-compliant consortia manufacturing technology allows to manufacture complete therapeutic consortia as a single drug substance in a single manufacturing process which strongly surpasses existing approaches in speed, reduced complexity, increased robustness and lower cost.

For further information please contact:

Dr Sam Possemiers – CEO
Christiane Verhaegen – CFO
Phone: +32.9.277.08.50
info@mrmhealth.com

Vietnam’s religious groups face state persecution, church leaders say

Church leaders in Vietnam say freedom to practice their religion, enshrined in the Constitution, is being undermined by the 2016 Law on Belief-Religion. Their comments support U.S. claims that the law allows the government to tighten control over religious activities.

The U.S. State Department’s annual report on International Religious Freedom 2021, released last week, included Vietnam on a list of countries where religious practices are being curtailed by the state.

The report, by the State Department’s Office of International Religious Freedom, found that: 

“Some religious leaders, particularly those representing groups that either did not request or receive official recognition or certificates of registration, reported various forms of government harassment, including physical assaults, detentions, prosecutions, monitoring, and denials of, or no response to, requests for registration and other permissions.”

RFA interviewed several religious dignitaries, who agreed with the State Department’s findings.

‘“The current Law on Belief-Religion 2016 significantly controls religion,” said Catholic priest Dinh Huu Thoai of the Redemptorist Church, which has been operating in Vietnam since 1925. 

“Specifically, when registering or changing the place of religious activities we have trouble with the concept of ‘religious organization.’ In the regulations it requires ‘written approval of the religious organization,’ which is required by law. The definition of religious organization varies from place to place.”

There are almost 7 million Catholics in Vietnam, according to Union of Catholic Asia News, making up 6.6 percent of the population. Even so, Father Dinh said the Catholic Church of Vietnam is still not considered a religious group in some parts of the country.

 “Some places consider parishes to be religious organizations or at least ‘affiliated religious organizations.’ They consider the registration or change of places of concentrated religious activities under the jurisdiction of the parish priest. And, if they are rigid considering only the diocese as a religious organization, they ask for the bishop’s text even if he is at the bishop’s house, not in the locality.”

Unregistered religious groups ‘persecuted’

Unregistered religious groups find it even harder to navigate the religious law, Father Dinh said.

“For example, the Unified Buddhist Church of Vietnam, Pure Hoa Hao Buddhism, Cao Dai Chan Truyen or Protestant groups that do not accept government intervention, are persecuted in all their religious activities.”

The U.S. State Department report also mentioned the Vietnamese government’s refusal to return hospitals, clinics and schools that local authorities took from the Catholic Church many years ago. When asked about this, Father Dinh said:

 “Properties of the Catholic Church and [other] religious orders in Vietnam have been confiscated, appropriated, borrowed by the Vietnamese communist government; borrowed but not returned. Hundreds of facilities including monasteries, schools, hospitals, orphanages, etcetera from 1954 in the North and from 1975 in the South. The owners of these establishments repeatedly demand their return in accordance with fair and civilized law, but the number of establishments returned is very small.” 

“There is a paradox going on today,” Father Dinh said. “The authorities give themselves the right to grant land to religious institutions, even though that land was bought by the religions themselves a long time ago, but they have to carry out procedures to return the right to use that land.”

“Why doesn’t the state use its rights to give the requisitioned religious facilities back to the owner rather than letting this problem drag on without knowing when it will be settled?”

Banned from traveling or meeting overseas visitors

The Redemptorist priest said the U.S. State Department report is lacking in that it omits to mention the issue of freedom of movement for many religious leaders.

“Some religious dignitaries, including myself, are arbitrarily banned from leaving the country. These dignitaries are not protected by the law but are arbitrarily banned by the police from leaving for an indefinite period.”

 “I myself have been banned from leaving the country since 2010 until now, which is almost 12 years, without any sign of them returning my passport along with my freedom of movement,” Father Dinh said.

Hua Phi, a high-ranking member of the independent religious group Cao Dai Chan Truyen, said his passport was confiscated in 2014 and is yet to be reissued, making it impossible for him to go abroad to attend a religious freedom conference in Southeast Asia.

Hua said all independent religious groups are restricted by the Vietnamese government in terms of their right to practice religion freely, with the government requiring groups to register in order to do so. He said even though many groups have a long history the government still makes it difficult for them to practice their religion.

Many religious organizations and followers are persecuted during religious holidays, according to Hua. He said local police keep a close eye on his movements during Cao Dai religious events, making him unable to travel to some parts of the country to practice his religion.

Hua said many dignitaries of the Interfaith Council of Vietnam, himself included, have been prevented from contacting foreign diplomatic missions when they come to learn about religious freedom in the region.

The U.S. State Department report states that representatives of the U.S. Embassy in Hanoi and the Consulate General in Ho Chi Minh City regularly raise concerns about religious freedom in Vietnam with local government officials and the Communist Party of Vietnam.

Father Dinh called on the international community and governments of ‘civilized countries’ to use economic leverage to put pressure on Hanoi to respect religious freedom.

RFA emailed Vietnam’s Ministry of Foreign Affairs and the Vietnam Government Committee for Religious Affairs with a request for comment on the U.S. report but received no response.

Maccabi Healthcare Services announces it is the first HMO in the world to include MeMed BV® test as part of routine care

Maccabi Healthcare Services announces it is the first HMO in the world to include MeMed BV® test as part of routine care

  • Groundbreaking host-response test distinguishes between bacterial and viral infection in just 15 minutes
  • Prompt differentiation enables early treatment to prevent deterioration and reduction of unnecessary prescription of antibiotics
  • Recent Maccabi pilot study of real world evidence data showed that in 21% of cases, doctors reached a more accurate diagnosis by using MeMed’s technology

Tel Aviv, Israel; June 7, 2022: Following US Food and Drug Administration (FDA) clearance of the MeMed BV® test, which helps physicians distinguish between bacterial and viral infections in just 15 minutes, Maccabi Healthcare Services announces today it is launching the test in all its urgent care centers around Israel. Maccabi is one of the largest health maintenance organizations (HMOs) in the world, with 2.5 million members and about 100,000 medical interactions per day.

Head of Maccabi’s health division, Dr. Miri Mizrahi Reuven, said: “The new test is a groundbreaking technology that allows for a faster and more accurate diagnosis in community medicine. The test is intended for use in cases where there is uncertainty around the origin of an infection – whether it is bacterial or viral – and the usual auxiliary tests are not sufficient. The test is especially beneficial in children and elderly patients who are at higher risk of medical deterioration if a bacterial infection is not treated in time. We have no doubt that this test can save lives.

The test is based on a technology that decodes the body’s immune response to infection, the ‘host response’, rather than focusing on detecting the presence of a microbe. This allows robust diagnosis when the infection site is inaccessible or unknown, even when the pathogen is undetectable using conventional tests, or when the cause of infection are emerging new pathogens. The MeMed BV® test enables better informed antibiotic treatment decisions, an essential tool in the fight against resistant bacteria, and helps physicians make a more accurate and timely diagnosis.

Maccabi Healthcare Services will make the technology available in all the organization’s urgent care centers starting this month.

A recent pilot conducted by Maccabi showed that in 21% of cases where the new test was used, physicians changed their medical decision in accordance with the test results, proving its effectiveness and relevance in the clinical setting.

Maccabi CEO Sigal Dadon Levy commented: “This is significant news in the world of medicine and we are proud to be the first health organization to provide this service widely. In the future, we believe that this type of device will become a central and leading tool in the diagnosis and treatment of infectious diseases.”

Dr. Eran Eden, CEO and co-founder of MeMed, added: “We are delighted to collaborate with Maccabi and for the opportunity to provide innovative medical solutions to its members. This is a partnership puts patients front and center. The test is now also being made available to physicians in the US and Europe. “

About Maccabi

Maccabi Healthcare Services is one of the world’s largest public healthcare providers with 2.5 million members. Maccabi has long been recognized, both in Israel and abroad, as a unique and innovative health care system which leads the way in cutting edge medical technology, comprehensive and integrated computerized information systems, cost–effective management, and sophisticated monitoring and evaluation tools.

About MeMed

Our mission is to translate the immune system’s complex signals into simple insights that transform the way diseases are diagnosed and treated, profoundly benefiting patients and society. For additional information on MeMed, please visit http://www.me-med.com

About MeMed BV®

PediatricsThe Lancet IDPLOS OneBMJ PedsEuropean Journal of Clinical Microbiology & Infectious Diseases

MeMed BV® is a first-of-its-kind immune-based protein signature test, developed and validated over the course of decade-long collaborations with leading academic and commercial partners. It provides physicians with an indispensable tool to help distinguish between bacterial and viral infections across multiple pathogens, even if the infection site is inaccessible or unknown. MeMed BV® measures and computationally integrates the levels of three immune system proteins: TRAIL, IP-10 and CRP. When run on the MeMed Key® platform, MeMed BV® provides a result within 15 minutes. MeMed BV® has been independently validated on thousands of patients and the results have been published in leading peer-reviewed journals (including , ,  ,  and ). The MeMed BV® test has received a CE Mark in Europe and AMAR clearance from the Israeli Ministry of Health.About MeMed Key ®

MeMed Key® is a pioneering technology platform, enabling highly sensitive measurements of multiple proteins, within minutes, at the point of need. It opens the way to quantification of a vast array of human proteins in healthy and disease states, where and when it actually matters. The MeMed Key® development program has been partially funded by the US Department of Defense and the EU Commission. MeMed Key® has received a CE Mark in Europe and AMAR clearance from the Israeli Ministry of Health.

:Media Contact

MeMed@consilium-comms.com